ADVA
14.4.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today extended its Ensemble Sync Director GNSS assurance software to integrate any third-party vendor’s GNSS receiver observables at scale. A key pillar of ADVA’s aPNT+™ technology, Ensemble Sync Director is now vendor-agnostic, providing defense-in-depth, resilient and assured PNT for more customers than ever before. Ensemble Sync Director can now transparently show and analyze GNSS observables from third-party receivers in even the largest deployments. This is key as synchronization based on satellite signals is vulnerable to failure, interference and cyberthreats, and so network operators urgently need to protect their critical timing with continuous monitoring and assurance. Now, they have the power to remotely detect issues with GNSS receivers from any vendor, helping to maintain high-quality timing performance, avoid disruptions and reduce operating costs.
“The number of GNSS devices in use is growing by the day, with many networks now relying on hundreds or even thousands of receivers. At the same time, the risks to satellite-based timing have never been greater, including the rising threat of jamming and spoofing attacks. By extending our GNSS assurance application capabilities beyond our own timing equipment, we’re empowering many more customers to protect their mission-critical synchronization in new or deployed infrastructure,” said Gil Biran, GM of Oscilloquartz, ADVA. “Our Ensemble Sync Director, with comprehensive GNSS assurance for both resilient and assured PNT, provides a simple, scalable and highly cost-efficient way to harness our unique experience and expertise in managing a huge number of GNSS-dependent network elements.”
ADVA’s Oscilloquartz GNSS assurance solution for integrating third-party receiver data is an extension of its Sync Director application, part of the Ensemble Controller network management platform. It offers centralized in-service monitoring and analysis of GNSS status and reliability as well as AI/ML-based prediction and prevention of obstruction, jamming and spoofing. Using topology and timing chain mapping, Ensemble Sync Director displays the entire timing network infrastructure in a user-intuitive graphical format. ADVA’s GNSS assurance capabilities are aligned with the goals of the DHS Resilient PNT Conformance Framework and future IEEE P1952 Resilient PNT Standard to protect critical infrastructure. Available from ADVA Professional Services, the new solution is ideal for network operators in telecoms, power utilities, financial trading, data centers and more, who need to ensure robust, reliable and resilient GNSS timing. It also offers significant value to system integrator vendors looking to add vital GNSS protection capabilities to their synchronization portfolio.
“People are increasingly aware of the risk factors affecting GNSS-reliant systems, as well as the heavy price that disruption can bring. Whether they are addressing PNT regulations or responding to the precarious geopolitical situation, more and more network operators are looking to take urgent action to safeguard their timing architectures with resilient and assured PNT capabilities. That’s why we’re extending our GNSS assurance software with real-time monitoring to integrate third-party timing receiver data and enable more customers to proactively protect their critical infrastructure,” commented Michael Port, VP of product line management at ADVA. “Scalable and easy to implement, our new offering adds instant value. What’s more, Ensemble Sync Director supports open integration, enabling end-to-end vendor-agnostic sync and timing network management.”
Further information is available in these slides: https://adva.li/third-party-gnss-assurance-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005726/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
